Navigation Links
Mirus Bio Awarded Grants & Contracts of Over $5 Million
Date:8/23/2007

MADISON, Wis., Aug. 23 /PRNewswire/ -- Mirus Bio Corporation today announced that it has been awarded five federal grants and contracts since January of this year totaling $5.4 million. They include:

-- Two Phase II SBIR grants totaling $2.4 million to further develop the

Company's Dynamic PolyConjugates(TM) siRNA delivery platform and

alternative nanoparticle technologies, focused primarily on improving

potency for liver applications;

[Principal Investigators Drs. D. Rozema and S. Wong]

-- One Phase II DOD contract for $1.8 million to optimize the Dynamic

PolyConjugates(TM) siRNA delivery platform for lung delivery and to

develop a treatment against respiratory infections;

[Principal Investigator Dr. H. Herweijer]

-- A Phase I SBIR grant for $0.3 million to improve gene expression

technologies; and

[Principal Investigator Dr. M. Sebestyen]

-- A previously announced Phase II SBIR grant for $0.9 million to develop

improved labeling technologies for microRNA, which is expected to lead

to new research products.

[Principal Investigator Dr. M. Watt]

"Securing this magnitude of support highlights the wide breadth of potential uses for this platform delivery technology and is a tribute to the outstanding cutting edge technology development being done by our research team," commented Jon Wolff, M.D., Mirus Bio's CSO and co-founder. "In this era of heightened competition for federal research grants, we are exceptionally pleased with this outcome and couldn't be more proud of our team as well as the grant procurement management that Dr. Hans Herweijer has provided. These funds are critical to maintaining our leadership position in nucleic acid delivery technologies."

Dynamic PolyConjugates(TM) (DPC) are an enabling platform for the targeted, systemic delivery of small interfering RNA (siRNA), a
'/>"/>

SOURCE Mirus Bio Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Mirus Bio secures $900K grant to develop research tool
2. Mirus Bio, Pfizer enter multimillion-dollar research agreement
3. Mirus Bio awarded patent on RNA delivery
4. Mirus granted European patent for gene therapy
5. Mirus provides low-cost way to modify genes
6. Mirus announces new method for making antibodies
7. Platypus adds Mirus VP to board of directors
8. Mirus receives $1.26 million SBIR grant to combat anemia
9. Small Tree Communications awarded $2.85M defense contract
10. Alfalight awarded $1.7M from Army Research Lab
11. UW Biomedical Engineering awarded $2.9 million research grant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... Pa. , July 28, 2015 ... and Drug Administration has accepted for review the company,s ... factor VIII single-chain (rVIII-SingleChain) for the treatment of hemophilia ... primary endpoints. Hemophilia A ... defective factor VIII; nearly all affected patients are male. ...
(Date:7/27/2015)... , July 27, 2015  Amgen (NASDAQ: ... second quarter financial results on Thursday, July 30, 2015, ... announcement will be followed by a conference call with ... the call from Amgen will be Robert A. ... members of Amgen,s senior management team. Live ...
(Date:7/27/2015)... ... July 27, 2015 , ... Brady ... new video: 3 Ways to GHS Labels . This video provides useful ... Harmonized System (GHS) by effectively labeling chemical containers. , “With the fourth and ...
(Date:7/27/2015)... NEW YORK , July 27, 2015 /PRNewswire-USNewswire/ ... today announced the winners of its annual ... basic research by scientists who have been supported ... early career scientists to pursue innovative ideas in ... generate "proof" of concept for the early detection, ...
Breaking Biology Technology:U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 2U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 3Amgen Announces Webcast of 2015 Second Quarter Financial Results 2Brady Releases “3 Roads to GHS Labels” Video 2Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 2Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 3Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 4Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 5Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 6
... Oct. 29 Elekta, a global leader ... Infinity*, the definitive new digital linear accelerator ... (VMAT), a very,fast Intensity Modulated Radiation Therapy ... at the 49th Annual Meeting of The ...
... FAJARDO, Puerto Rico and CORONA, Calif., Oct. ... Watson Pharmaceuticals, Inc. announced,today that under a ... Inc., Watson has launched Tilia(TM) Fe (norethindrone ... fumarate tablets), the generic,version of Warner Chilcott,s ...
... ... Exhibition, SAN ... in regenerative medicine, announced today that findings from,a preclinical study being ... Exhibition demonstrate the ability,of the Tengion Neo-Bladder Augment(TM) to restore bladder ...
Cached Biology Technology:Elekta Announces Elekta Infinity - a New System for Faster and More Precise Treatment of Cancer Tumors 2Elekta Announces Elekta Infinity - a New System for Faster and More Precise Treatment of Cancer Tumors 3Warner Chilcott and Watson Pharmaceuticals Announce Launch of Tilia(TM) Fe 2Warner Chilcott and Watson Pharmaceuticals Announce Launch of Tilia(TM) Fe 3Warner Chilcott and Watson Pharmaceuticals Announce Launch of Tilia(TM) Fe 4Preclinical Efficacy Data Demonstrate Ability of Tengion's Neo-Bladder Augment to Restore Bladder Function 2Preclinical Efficacy Data Demonstrate Ability of Tengion's Neo-Bladder Augment to Restore Bladder Function 3
(Date:7/13/2015)... Calif. , July 13, 2015 ... developer of human interface solutions, today announced sampling ... touch and display driver integration (TDDI) product targeting ... the first to combine Synaptics , best-in-class ... proven display driver technology developed in the company,s ...
(Date:7/9/2015)... , July 9, 2015  Unchained Labs ... announcing its acquisition of Avid Nano. Avid Nano ... scattering (DLS) systems.    Also today, ... fastest and easiest to use protein sizing system. ... measures a protein,s hydrodynamic size, size distribution, aggregation ...
(Date:7/8/2015)... SAN DIEGO , July 8, 2015 /PRNewswire/ ... of cell-free molecular diagnostics, today announced the launch ... of the Company,s Precision Cancer Monitoring℠ (PCM) technology ... patients receiving one or a combination of the ... and Opdivo® (nivolumab), a PD-1 inhibitor. The 50-patient ...
Breaking Biology News(10 mins):Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4
... infection via the innate immune system. Defensins are proteins ... anti-HIV activity. However, the mechanism by which the defensins ... on February 17 in advance of publication in the ... Investigation, Theresa Chang and colleagues from Mount Sinai School ...
... cancers from Nigeria, Senegal and North America has found ... be diagnosed with a more virulent form of the ... the University of Chicago, working with colleagues at the ... North Carolina, found that breast cancers in African women ...
... in the deep recesses of the world’s oceans. What ... cold and extreme pressure of such an environment? , ... of California, San Diego, and their colleagues have used ... accurate portrayal of deep sea life forms and how ...
Cached Biology News:Study reveals dramatic difference between breast cancers in US and Africa 2Study reveals dramatic difference between breast cancers in US and Africa 3Study reveals dramatic difference between breast cancers in US and Africa 4Advancements In Genomics Foster Deep Sea Discoveries 2
Rabbit polyclonal to XPC ( Abpromise for all tested applications). Antigen: Synthetic peptide from N-terminus of Human XPC conjugated to a carrier protein Entrez Gene ID: 7508 Swiss ...
Rabbit polyclonal to FANCG ( Abpromise for all tested applications). Antigen: Synthetic peptide: MSRQTTSVGSSC, corresponding to amino acids 1 - 12 of Human FANCG. Entrez GeneID: 2189 Swis...
Rabbit polyclonal to DcR2 ( Abpromise for all tested applications). entrezGeneID: 8793 SwissProtID: Q9UBN6...
...
Biology Products: